Clinical trials located in


Augsburg city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Augsburg, established by the Romans in 15 BC, is one of Germany’s oldest cities, boasting a rich history that spans over 2000 years. It played a pivotal role in the Holy Roman Empire and became a central hub for the banking and social reform activities of the Fugger and Welser families in the 15th and 16th centuries. The city is renowned for its water management system, a UNESCO World Heritage site, reflecting innovative engineering from medieval times. Augsburg also hosts the Peace Festival every August 8th, commemorating the Peace of Augsburg of 1555.

  • CT-EU-00121560

    Study of the safety and effectiveness of GLSI-100 in patients with HER2-positive breast cancer

    The study concerns the treatment of patients with HER2/neu-positive breast cancer. Treatment will include GLSI-100 immunotherapy and comparison to placebo. GLSI-100 consists of GP2 peptide and GM-CSF, protein substances that are designed to strengthen the body’s immune response, i.e. natural protection against diseases.

    The aim of this study is to determine how effective and safe GLSI-100 therapy is compared to placebo in preventing breast cancer recurrence after standard treatment. The study is aimed at people at high risk of disease recurrence who have completed both preoperative and postoperative therapy based on trastuzumab, a drug used to treat breast cancer.

    The study will assess invasive breast cancer-free survival (i.e. the time from the first dose of the drug to the moment of disease recurrence or death from any cause), invasive disease-free survival (i.e. the time from the first dose of the drug to the moment of any disease recurrence or new cancer), remote disease (i.e. time until disease recurrence in a place other than the breast or death).

    The study also includes an assessment of the participants’ quality of life both at the beginning and over the next 36 months, as well as an analysis of the body’s immune response to treatment.

  • Study of Barzolvolimab (CDX-0159) in Adult Patients with Eosinophilic Esophagitis

    This clinical study involves patients with Eosinophilic Esophagitis (EoE), a condition where a type of white blood cell, called eosinophils, builds up in the lining of the esophagus. This can lead to difficulty swallowing and other issues. The therapy being tested is barzolvolimab (CDX-0159).

    The goal of the study is to test the effectiveness and safety of barzolvolimab in adults with active EoE. There are two main groups in this study: one will receive barzolvolimab, and the other will receive a placebo, followed by barzolvolimab.

    Participants will receive treatment through subcutaneous (under the skin) injections every four weeks for 24 weeks. In the barzolvolimab group, patients will get 300 mg of the medication from the start. In the other group, patients will receive a placebo for the first 16 weeks and then switch to barzolvolimab for the remaining 8 weeks.

    The study will look at changes in the number of eosinophils and other cells in the esophagus, as well as symptoms like difficulty swallowing. Side effects and other health changes will be monitored throughout the study.

    • Placebo
    • barzolvolimab
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • Study of the drug combination mRNA-4157/V940 and Pembrolizumab in the treatment of melanoma

    The aim of this clinical trial is to test whether a new drug called mRNA-4157/V940 in combination with pembrolizumab can help prevent the recurrence of melanoma in people who have already had it. Currently, mRNA-4157/V940 is what is called “individualized neoantigen therapy,” which means it is a therapy created specifically for each patient based on their cancer cells. Doctors give this drug along with pembrolizumab, a drug that helps the immune system fight cancer cells.

    The main goal of this study is to determine whether taking V940 and pembrolizumab together is more effective in preventing melanoma recurrence than taking pembrolizumab alone. Researchers will closely monitor how long it takes for the cancer to return or spread. The study will last for approximately 74 months.

    • mRNA-4157/V940
    • placebo
    • Pembrolizumab
  • Study Comparing Asciminib and Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia

    This study examines the effects and tolerance of two drugs, asciminib and nilotinib, for treating a specific type of leukemia called Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in its chronic phase. The participants are adults who have been newly diagnosed and have not received previous treatment for this condition. They will be randomly assigned to receive either asciminib or nilotinib. The study aims to see which drug is better tolerated and how effective they are. Throughout the study, participants will be monitored for any side effects and the progress of their treatment until they either experience significant side effects, the disease progresses, or they decide to stop the treatment. Follow-up checks will also be conducted after the treatment ends.

    • Asciminib
    • Nilotinib
  • Testing the safety and effectiveness of astegolimab for chronic lung disease

    The aim of this study is to see if a drug called astegolimab will be effective and safe in people with a lung disease called chronic obstructive pulmonary disease, or COPD. During this study, patients will be divided into 2 groups. One group of patients will receive the drug, the remaining patients will receive a placebo to compare the results. Both groups will not know what they are getting. The study was particularly interested in people suffering from COPD (chronic obstructive pulmonary disease) who smoked or still smoke and often get sick because of it.

    • Astegolimab
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    • Tozorakimab
  • Study of Tucatinib, Trastuzumab and Pertuzumab in the treatment of HER2+ metastatic breast cancer

    The study is aimed at patients with HER2-positive breast cancer whose disease has spread locally, i.e. close to where it started, and cannot be surgically removed, or has spread to other parts of the body. Treatment in this study includes a combination of drugs: tucatinib (also known as TUKYSA, ONT-380, ARRY-380), trastuzumab (Herceptin, Herceptin Hylecta), and pertuzumab (Perjeta). Some patients will receive a placebo instead of tucatinib.

    All patients will receive trastuzumab and pertuzumab, plus either tucatinib or placebo. Trastuzumab is administered intravenously (IV) or subcutaneously, and pertuzumab is administered intravenously. In some cases, trastuzumab and pertuzumab may be administered subcutaneously in combination.

    The aim of the study is to check whether tucatinib in combination with trastuzumab and pertuzumab works better than placebo. This will also check what side effects may occur while taking this drug combination. Side effects are any adverse effects a drug may have on the body in addition to treating the disease.

    The study includes patients who have already undergone 4-8 cycles of pre-treatment with trastuzumab, pertuzumab and taxane as first-line treatment for advanced breast cancer, and do not show disease progression after completion of this pre-therapy. Patients can have both positive and negative hormone receptor status.

    • Pertuzumab
    • Tucatinib
    • Trastuzumab
  • To study the efficacy and safety of Alpelisib and Fulvestrant in patients with advanced breast cancer after prior treatment

    The study is aimed at patients with advanced breast cancer, which is hormone-dependent (HR+) and HER2-negative, which means that cancer cells develop under the influence of hormones and at the same time do not have a large number of HER2 receptors. Patients must have a mutation in the PIK3CA gene and progressive cancer after previous therapy with CDK4/6 inhibitors and aromatase inhibitors.

    The study will use two drugs: Alpelisib, administered in the form of tablets, and Fulvestrant, administered as intramuscular injections. Both of these therapies will be compared with placebo in combination with fulvestrant. The aim of the study is to evaluate the effectiveness and safety of combined treatment with alpelisib and fulvestrant compared to placebo plus fulvestrant.

    • Alpelisib
    • Fulvestrant
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing new treatment for advanced cancers with changes in the HER2 gene

    This medical study aims to evaluate the effectiveness of a new medication, Zongertinib (BI 1810631), in individuals facing advanced cancer, particularly cases where the cancer has originated from alterations in the HER2 gene. The study comprises two main sections. In the initial phase, the focus is on individuals who have not responded to previous cancer treatments. The primary objective is to determine the highest dose of BI 1810631 that can be safely administered. Following this, the study progresses to the second part, where the emphasis shifts to testing whether the medication can reduce the size of tumors in patients with a specific type of lung cancer. Participants will continue in the study for as long as the treatment proves beneficial and manageable for them. Regular health check-ups and tumor analyses will be conducted to monitor any potential side effects resulting from the medication.

    • Zongertinib/BI 1810631
  • Comparison of new treatment and standard care for lymphoma patients

    A new approach to treating Lymphoma, a type of cancer originating in cells constituting the body’s immune system, is being tested in this trial. Comparison is being made between a new treatment, referred to as MB-CART2019.1, and the presently conventional treatment. The MB-CART2019.1 therapy is designed to target the aberrant B cells responsible for this form of cancer. In the process of creating MB-CART2019.1, cells are extracted from the patient’s own body, modified in the laboratory to combat cancer, and subsequently reintroduced into the patient. Participants in this trial will receive either MB-CART2019.1 or the standard treatment. The standard treatment involves the use of a drug combination (rituximab, gemcitabine, oxaliplatin (R-GemOx) or bendamustine, rituximab (BR) + polatuzumab vedotin). The objective is to assess whether MB-CART2019.1 demonstrates superior efficacy compared to these conventional drugs. Patient progress will be closely monitored for approximately one year to evaluate their well-being.

    • Gemcitabine
    • Polatuzumab vedotin
    • Bendamustine
    • Rituximab
    • Oxaliplatin
    • Rituximab
  • Breast cancer study: evaluating pre- and post-surgery treatment with Dato-DXd, durvalumab, and pembrolizumab

    The study focuses on triple-negative breast cancer (TNBC) or low hormone receptor and HER2-negative breast cancer. The effectiveness and safety of two different therapies will be evaluated.

    The experimental therapy includes Datopotamab Deruxtecan (Dato-DXd) and Durvalumab, both before surgery (neoadjuvant) and after surgery (adjuvant). In cases of remaining disease, patients may also receive chemotherapy. Patients with BRCA gene mutations may receive Olaparib.

    The comparative therapy involves Pembrolizumab combined with chemotherapy, also before and after surgery. In cases of remaining disease, patients may receive additional chemotherapy and Olaparib.

    The goal is to determine which therapy is more effective and safer in treating TNBC or low hormone receptor and HER2-negative breast cancer.

    The study includes adults with newly diagnosed, untreated breast cancer, confirmed histologically as stage II or III, with appropriate physical fitness. Patients with a history of other cancers, active viral infections, or pregnant or breastfeeding women are excluded.

    • Epirubicin
    • Doxorubicin
    • Dato-DXd
    • Carboplatin
    • Pembrolizumab
    • olaparib
    • Capecitabine
    • Durvalumab
    • Cyclophosphamide
    • Paclitaxel
  • Discovering new treatments for breast cancer with trastuzumab deruxtecan

    This clinical trial is evaluating a new treatment, Trastuzumab Deruxtecan (T-DXd), for early-stage, HER2-positive breast cancer. The study compares T-DXd alone or in sequence with other treatments against the standard therapy. It’s designed for patients with high-risk, non-metastatic breast cancer and aims to find out if T-DXd is more effective and safe. The focus is on how well patients respond to the treatment and their overall and disease-free survival rates.

    • Doxorubicin
    • Trastuzumab deruxtecan
    • Cyclophosphamide
    • Trastuzumab
    • Pertuzumab
    • Paclitaxel
  • Study of Early Breast Cancer Using Camizestrant or Hormone Therapy for Patients at Risk of Recurrence After At Least 2 Years of Standard Therapy

    The clinical trial focuses on patients with early-stage ER+/HER2- breast cancer, meaning the cancer is hormone-receptor-positive (ER+) and does not have an excess of the HER2 protein (HER2-). Participants must have an intermediate or high risk of disease recurrence and must have completed definitive locoregional therapy (such as surgery or radiotherapy) and at least 2 years but not more than 5 years of standard hormone therapy.

    The aim of the study is to assess the efficacy and safety of the drug Camizestrant (AZD9833) compared to standard hormone therapy, which may include aromatase inhibitors (e.g., letrozole, anastrozole, exemestane) or tamoxifen.

    Key measures will include the time to the recurrence of invasive breast cancer, invasive disease-free survival, distant relapse-free survival, overall survival, and the safety of the therapies used.

    Both women and men over 18 years old who meet specific criteria can participate in the study. Therapeutic effects and potential side effects will be monitored during the treatment. Patients will be observed for 10 years from the time of randomization into one of the study groups.

    • camizestrant
    • Anastrozole
    • Letrozole
    • Exemestane
    • tamoxifen
  • Study of Dato-DXd and durvalumab in persistent triple-negative breast cancer

    This trial is about testing a combination of new treatments for triple-negative breast cancer which hasn’t fully responded to the first line of treatment. The new treatment includes a drug called Dato-DXd and a known drug called Durvalumab, both administered individually, or as a combination. This is compared to an already established treatment recommended by the doctor. The researchers are mainly interested in delaying the return of the cancer, and if the new drug with or without Durvalumab does a better job at this than the doctor-recommended treatment. Along with this main goal, the trial will also monitor how these treatments affect patients’ routine activities, their well-being, their levels of fatigue, the amount of Dato-DXd and related components present in the body, and any side effects and potential risks associated with these treatments.

    • Dato-DXd
    • Pembrolizumab
    • Capecitabine
    • Durvalumab
  • Tozorakimab study for viral lung infection in hospitalized patients needing oxygen

    This clinical trial evaluates the effectiveness and safety of tozorakimab for hospitalized patients with viral lung infections requiring supplemental oxygen. The study involves two groups: one receiving tozorakimab and the other a placebo, alongside standard care. The main goal is to see if tozorakimab can lower the risk of death or the need for intensive respiratory support. The study involves adult patients and aims to measure various health outcomes, including mortality rates and the length of intensive care and oxygen support.

    • Tozorakimab
  • Drug study – AZD9833 in advanced HR+/HER2- breast cancer with ESR1 mutation

    The study focuses on advanced breast cancer, specifically hormone receptor-positive (HR-positive) and human epidermal growth factor receptor 2-negative (HER2-negative) cases. These patients show an ESR1 gene mutation that might cause current treatments to stop working well. The body’s inability to control cell growth leads to tumors in the breast, and when these tumors spread to other parts of the body, it becomes advanced cancer.

    AZD9833, an unapproved trial drug, will be compared with two existing treatments: palbociclib, abemaciclib, and ribociclib (which block tumor growth), and letrozole and anastrozole (aromatase inhibitors, AI), to see if it works better when combined with palbociclib, abemaciclib, or ribociclib in patients with the ESR1 mutation.

    Participants will either continue their current combination of AI and CDK4/6 inhibitor or switch to AZD9833 and a CDK4/6 inhibitor. The goal is to see which combination is better at extending the time before the cancer gets worse and to learn more about AZD9833’s safety.

    Participants in this trial will have been receiving combinations of an AI and a CDK4/6 inhibitor beforehand. During the trial, they will remain on the same CDK4/6 inhibitor.

    Participants will be split into two groups: Group A will receive AZD9833, a CDK4/6 inhibitor, and a placebo. Group B will receive an AI, a CDK4/6 inhibitor, and a placebo.

    The treatments will be taken daily in 28-day cycles as follows: either AZD9833 or an AI plus the placebo. If taking abemaciclib: twice daily for 28 days. If taking palbociclib or ribociclib: once daily for 21 days, followed by a 7-day break. This 28-day cycle will repeat for the duration of participation in the trial.

    • Camizestrant
    • Luteinizing hormone-releasing hormone (LHRH) agonist
    • Abemaciclib
    • Palbociclib
    • Ribociclib
    • Anastrozole
    • Letrozole
  • Breast cancer study: capivasertib, CDK4/6 inhibitors and fulvestrant in patients with advanced or metastatic hormone-sensitive breast cancer

    The study concerns patients with locally advanced (inoperable) or metastatic breast cancer that is positive for hormone receptors (HR+) and negative for human epidermal growth factor receptor 2 (HER2-). The therapy being investigated in this project is a combination of Capivasertib, CDK4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib) and Fulvestrant.

    The aim of the study is to evaluate the effectiveness and safety of adding Capivasertib to therapy with CDK4/6 inhibitors and Fulvestrant and to investigate whether this combination provides additional benefits. Different doses and schedules of these drugs will be tried, and potential side effects will be assessed.

    The study is aimed at adult patients, both women and men, who meet certain criteria regarding previous treatment and health status. It is required, among other things, that patients’ breast cancer is histologically confirmed as HR+ and HER2- and that they are qualified for treatment with Fulvestrant and at least one of the CDK4/6 inhibitors (Palbociclib, Ribociclib or Abemaciclib).

    The trial will include two phases: an initial Phase Ib, which will determine drug dosing, and a Phase III, which will further evaluate the effectiveness and safety of the drug combination compared to standard treatment. Progression-free survival and the rate of survival without health condition deterioration will be key indicators for assessing the effectiveness of therapy.

    People with other active cancers, unstable cardiovascular diseases, or serious metabolic disorders requiring insulin treatment cannot participate in the study.

    • Capivasertib
    • Abemaciclib
    • Palbociclib
    • Ribociclib
    • Fulvestrant

See more clinical trials in other cities in Germany: